Clinical Research Directory

Inclusion Criteria: 1. Relapsed and refractory B-cell lymphoma with: Relapsed or refractory disease after ≥2 lines of chemotherapy including rituximab and anthracycline and either having failed after autologous or allogeneic hematopoietic stem cell transplantation (ASCT); 2. Patients must have evaluable evidence of disease, including minimal residual disease (MRD); 3. Double positive expression of CD19 / CD20 in B cells; 4. Ages 1 to 80 years, including boundary values; 5. ECOG score 0-3 points; 6. Women of childbearing age (15-49 years old) must receive a pregnancy test within 7 days prior to initiation of treatment and the results are negative; male and female patients with fertility must use an effective contraceptive to ensure 3 months after discontinuation of treatment during the study period not pregnant inside; 7. Patients who voluntarily sign informed consent and are willing to comply with treatment plans. Exclusion Criteria: 1. patients with organ failure: * Heart: NYHA heart function grade IV; * Liver: Grade C that achieves Child-Turcotte liver function grading; * Kidney: kidney failure and uremia; * Lung: symptoms of respiratory failure; * Brain: a person with a disability; 2. Active infections that are difficult to control; 3. Human immunodeficiency virus (HIV) positive; 4. Liver and kidney function: total bilirubin \> 5 × ULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \> 5 × ULN, serum creatinine clearance rate 60mL / min; 5. GVHD ≥ 2 or anti-GVHD treatment; 6. intracranial hypertension or unconsciousness; respiratory failure; diffuse vascular internal coagulation; 7. pregnant or lactating women; 8. The patient does not agree to use effective contraception during the treatment period and for the next 3 months; 9. Patients who participate in other clinical studies at the same time; 10. The investigator believes that there are other factors that are not suitable for inclusion or influence the subject's participation or completion of the study.